http://www.immunogen.com/about-us
http://finance.yahoo.com/q/h?s=IMGN Our mission is to be the leader in the application of monoclonal antibodies for the treatment of cancer. We aim to achieve this by exploiting our expertise and experience in the identification of potential biological targets for cancer treatments, the development and humanization of monoclonal antibodies, and the creation of potent cell-killing agents designed for delivery by antibodies. Our Targeted Antibody Payload(TAP) technology uses tumor-targeting antibodies to deliver a highly potent cell-killing agent specifically to cancer cells to kill these cells with minimal damage to healthy tissue.
We are committed to the highest standards of scientific excellence and integrity for the benefit of patients, the medical community, our partners, shareholders and employees.